Patents and Misplaced Angst: Lessons for Translational Stem Cell Research from Genomics  by Mathews, Debra J.H. et al.
Cell Stem Cell
ForumPatents and Misplaced Angst: Lessons
for Translational Stem Cell Research from GenomicsDebra J.H. Mathews,1 Robert Cook-Deegan,2 and Tania Bubela3,*
1Johns Hopkins Berman Institute of Bioethics, 1809 Ashland Avenue, Baltimore, MD 21205, USA
2Institute for Genome Sciences & Policy and Sanford School of Public Policy, Duke University, Box 90141, 304 Research Drive, Durham,
NC 27708-0141, USA
3School of Public Health, Edmonton Clinic Health Academy, 11405 87 Avenue, Edmonton, AB, T6G 1C9, Canada
*Correspondence: tbubela@ualberta.ca
http://dx.doi.org/10.1016/j.stem.2013.04.015
Realizing the therapeutic potential of both stem cell and genomics research requires harnessing the respec-
tive strengths of academic, biotechnology, and pharmaceutical sectors, supported by policies and legal
incentives for multisectorial collaboration. Here, we discuss issues facing these fields and lessons from
the genomics sector that apply to stem cell research.The intellectual property rights (IPRs) and
policy contexts surrounding stem cell and
genomic research over the past 3
decades share many features, including
complex and lengthy translational path-
ways, significant uncertainties in the
scope of IPRs, diverse actors in a com-
plex innovation ecosystem, and working
with human materials. This ecosystem,
dominated by academic researchers,
also includes industry, regulators, fun-
ders, health system payors and, most
importantly, patients and the public.
There are also some stark differences,
however. The genomics field took flight
in the late 1980s, a decade before the
derivation of human embryonic stem cells
(hESCs). Genomics was also not compli-
cated by the range of research policies
from restrictive to permissive that hESC
research has faced in the United States
(US) and abroad. Publicly generated
genomic data were subject to broad and
rapid sharing, in contrast to the history
of controversy and protracted negotia-
tions over access to early hESC lines
that were covered by patents andmaterial
transfer agreements. State governments
in the US did not become major funders
of genomics to the same extent as stem
cell research, nor did nations develop
national innovation policy around geno-
mics to the extent that they did for stem
cell research. Differences aside, these
two fields are intimately connected by
the relationship of their research materials
to individual humans, and the stem cell
field may learn from genomics, which
has developed both infrastructure and
policies to support precompetitive,508 Cell Stem Cell 12, May 2, 2013 ª2013 Elmultisectorial research required to capi-
talize on the plethora of data on gene
function, disease pathways, target identi-
fication, and more rational therapeutic
interventions supported by omics-based
diagnostics.
The R&D Landscape
for Translational Genomics
and Stem Cell Research
Both stem cell research and genomics
have enjoyed tremendous public atten-
tion, buoyed by cycles of ‘‘hype and
hope,’’ though with moderated expecta-
tions in recent years. A proxy measure
for innovative activity in both fields is the
number of patents filed; patents are
generally considered incentives for
technological innovation. In both fields,
patents peaked and dropped in the first
decade of the 21st century and have since
stabilized, except for induced pluripotent
stem cell (iPSC)-related claims, which
are defying the general downward trend
since 2008 for all stem-cell-related
patents (Figure 1). Japan, California,
Massachusetts, and the UK dominate
iPSC filings (Figure 2), and the increase
in patent filings reflects the global
momentum of iPSC research as part of
the international landscape. DNA patents
(patents containing one or more claims
based on or explicitly mentioning a
nucleic acid or DNA-specific construct)
rose rapidly in the mid-1990s, and many
seminal ‘‘gene patents’’ were filed at
more or less the same time as those for
stem cell biology.
Initial expectations that a few patented
inventions might give rise to blockbustersevier Inc.commercial applications have largely
shifted to an understanding of a complex
ecosystem with broadly distributed
cumulative innovation. Both fields have
discovered the very slow research and
development cycle for biomedical prod-
ucts and services. Therapies may take
between 10 and 15 years to reach the
clinic—a timespan that will likely be even
longer for cell-based interventions—
while patent terms extend for 20 years
plus marginal extensions to account
for regulatory approval processes and
necessary clinical studies. Indeed, key
patents over hESCs are set to expire
with only three clinical trials worldwide in
early phases. Similarly, only one clinical
trial using reprogrammed cells has
received preliminary approval in Japan.
A far greater understanding of iPSC
biology and safety will be required
before regulators are willing to approve
broad human use. Both iPSCs and hESCs
raise significant regulatory concerns,
including safety and efficacy. Both are
unstable in culture. It is therefore unlikely
that key patents that issue in the near
term will still be in force if or when iPSCs
enter the clinic as approved medical
products.
Commentators note this long and
difficult road to the clinic, particularly for
cell-based interventions, and the need
for stem cell research ‘‘to be incubated
in academia much longer before it is
ready to graduate into a business that
can commercialize the technology and
deliver real products’’ (Giebel, 2005).
Reflecting this dominant role of the
public sector in both fields, universities
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Figure 1. Analysis of Keywords in Claims Using Sets of Synonyms
for Stem Cell Types in International Patent Application Filings
Patents were searched to 2011 with no date restrictions using the algorithm
developed by Bergman and Graff (2007) in Thomson Innovation.
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tutions own an unusually
high fraction of relevant
patents. Through 2006, aca-
demic institutions were as-
signees on over 40% of stem
cell patents (Bergman and
Graff, 2007), a strikingly
similar figure to the 39%
of DNA patents assigned to
such institutions in the early
years of genomics (Cook-
Deegan and McCormack,
2001). Likewise, in both fields,
startup firms, many spun out
of academic institutions,
dominated the early land-
scape, though larger, estab-
lished firms have since
entered the genomics field
through mergers and acquisi-tions, such as GlaxoSmithKline via its
acquisition of Human Genome Sciences.
Industry has been slower to enter
the stem cell field due to difficulties in
accessing venture capital, the slow
emergence of business models specific
to cell-based therapies, uncertain regula-
tory pathways, and social and political
controversy about the usage of hESCs,
with spillover effects to other stem cell
types. Regenerative medicine remains
dominated by small biotechnology com-
panies focused on tools and nonthera-
peutic products (48%), as well as services
and manufacturing (9%).
Landmark Litigation and
Uncertainty in Patent Scope
Both genomics and regenerative medi-
cine have generated controversy. Conflict
has erupted not only about patentability
and ownership of human biological mate-
rial, but also over licensing strategies and
business models, raising the ire of the
public, patients, and NGO communities
(Gold and Carbone, 2010). Genomics
companies, such as Myriad Genetics,
find themselves defending patents in
court; the Wisconsin Alumni Research
Foundation (WARF), which holds patents
over hESCs and distributes them through
WiCell, faces patent expirations before
many hESC applications are even in clin-
ical trials, let alone on the market. Gene
and hESC patent disputes have resulted
in a reevaluation of patentable subject
matter, which may have broad implica-
tions for biotechnology generally. TheSupreme Court has accepted two cases
for appeal that turn on interpretation of
Section 101 of the US Patent Act, which
holds that patents can be granted for
any ‘‘new and useful process, machine,
manufacture, or composition of matter,
or any new and useful improvement
thereof.’’
In 2012, the US Supreme Court unani-
mously decided Mayo v. Prometheus, a
landmark case about patenting a method
to guide drug doses for anti-inflammatory
drugs based on measuring a drug metab-
olite level. In Mayo v. Prometheus, the
Court was quite clear that it saw an
important reason for establishing limits
on patentable subject matter: the fear
that patent exclusivity might preempt
science and innovation. Practically,
Mayo v. Prometheus changed how
method claims are examined by the US
Patent and Trademark Office, although
exactly how and to what extent is only
now being worked out.
The second case, Association of
Molecular Pathology v. US Patent and
Trademark Office (now AMP v. Myriad),
was argued before the US Supreme Court
on April 15, 2013, with a ruling expected
by July. Here, the Supreme Court ad-
dressed a deceptively simple question:
‘‘Are human genes patentable?’’ Its
decision will thus directly confront
‘‘composition of matter’’ claims (as
opposed to the method claims in Mayo
v. Prometheus). If the Supreme Court
follows its logic in Mayo v. Prometheus,
and says human genes cannot beCell Stem Cell 12, May 2patented, then this could spill
over to the parallel question
in cell biology: ‘‘Are human
cells patentable?’’ The three
WARF patents, for example,
are based on a common
specification of the invention,
with claims on methods
and ‘‘compositions’’ that
were discovered rather than
invented. One WARF patent
has been invalidated. The
other two were reexamined
and reissued, but would be
newly subject to challenge,
this time not as a result
of the administrative reexa-
mination but because of
new Supreme Court juris-
prudence. Regardless, the
first of the WARF patents willexpire in 2015 (just as the broadest pat-
ents challenged in AMP v. Myriad will
expire in 2014 and 2015); thus, the main
impact of the decisions will be on future
cell-based inventions and discoveries. It
will indeed be a deep irony for genomics
and stem cell research if, just as key pat-
ents near expiration, the Supreme Court
rules that the broadest patent claims en-
forced for over a decade should never
have been granted.
hESC patents have already been
determined as ineligible for patent by the
European Patent Office, reviewed by the
European Court of Justice in Bru¨stle v.
Greenpeace, but for reasons connected
to exclusions in the European Union’s
Biotechnology Directive of 1998 and the
‘‘ordre public’’ provision of European pat-
ent law. The same outcome—that hESCs
are ineligible for patents—might thus be
reached for entirely different reasons in
the world’s two largest and most
economically significant patent jurisdic-
tions (Europe and the US), though geneti-
cally modified cells (e.g., iPSCs), can be
patented in both. This illustrates how
criteria for patentable subject matter of
stem cells and cell-based inventions
may prove particularly fraught with uncer-
tainty despite convergence in outcomes.
Indeed, even the patenting of modified
cell lines has generated controversy,
although on a smaller scale, with ongoing
uncertainty over the priority of claims over
methods for creating iPSCs. Overall, such
uncertainty—related not only to what can
be patented, but also to overlapping, 2013 ª2013 Elsevier Inc. 509
Figure 2. Geographic Location of Assignees of International Patent Application Filings by Stem Cell Type in Claims of International Patent
Application Filings
Patents were searched to 2011 with no date restrictions using the algorithm developed by Bergman and Graff (2007) in Thomson Innovation. Assignees are
mapped by postal code in North America and by country in the rest of the world. We clustered the patents using synonyms for three general stem cell types:
all adult stem cells, human embryonic stem cells, and induced pluripotent stem cells.
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nant feature of both stem cell and genetic
research—diminishes the value of patents
within a portfolio and leads to a need
for more creative thinking about the
management of IPRs, including patents.
Lessons Drawn for the
Management of IPRs
While uncertainty about what can be
patented hangs over both fields, the
more important lessons from genomics
are about how information and materials
are shared in research and development,
including how exclusive rights are used.
Complexities and lengthy timelines in the
translational pathway, combined with
uncertain patent scope and the domi-
nance of academic institutions in the
stem cell field, point to the need to bolster
incentives for collaborative, multinational,
multidisciplinary, and multisectorial
research and development. Patents are
often considered powerful incentives
for technological innovation, especially
in biotechnology and pharmaceutical
sectors. However, the overuse and inap-
propriate management of patents may
counterintuitively hinder the precompeti-
tive collaborations essential for clinical
translation (Bubela et al., 2012), and ulti-
mately for furthering the goal of improved
global health. Lessons from genomics tell
us that IPRs on genes and methods do510 Cell Stem Cell 12, May 2, 2013 ª2013 Elinduce private R&D investment but
may also hinder such investment when
there is a shadow of uncertainty about
infringement liability. The ‘‘anticommons’’
problem for follow-on research did not
materialize with the intensity some feared
for genomics research, but this was
mainly because most scientists ignored
IPRs. Anticommons effects (the under-
utilization of inventions) may occur when
multiple, overlapping patents make it
difficult for innovators to identify all of
the relevant rights holders and then
negotiate licenses from multiple rights
holders. The effects remain especially
problematic for the multiple licenses
necessary for product and platform
development (e.g., community research
resources and diagnostics), where IPRs
may be more strictly enforced.
One conclusion from genomics is clear,
however. Data that are shared rapidly and
freely are used more, including in the
development of more commercial prod-
ucts. Celera human genomic sequence
data that were less widely available and
subject to contractual limits had 20%–
30% percent fewer citations (less scienti-
fic use) and fewer diagnostic products
(commercialization) than freely available
sequence data from the public Human
Genome Project deposited under the
Bermuda Principles (Williams, 2013).
Wider use of freely available data in sci-sevier Inc.ence makes intuitive sense, but more
diagnostics means that open science
also matters for the development of
practical applications and commercial
products. Open science lifts all boats;
the corollary is that use restrictions
hamper both science and commerce.
The early history of hESC research was
shrouded in controversy, not only socially
and politically, but also over contractual
use restrictions and patent rights with
reach-through clauses. As the patents
near expiration, their main impact seems
to have been as a tax on innovation
that benefited the patent-holders, but
also slowed the field. This belies the con-
ventional wisdom dominating technology
transfer, and, perhaps ironically, univer-
sities are the main points of friction.
An overemphasis on IPRs may also
hinder collaborative research, which is
theorized to facilitate more efficient use
of resources and knowledge through the
reduction of negotiating costs associated
with proprietary holdings, the avoidance
of duplicative research within a secretive
environment, and the use of standard
research tools andmethods, underpinned
by repositories for data and biological
materials. We use the term ‘‘theorized’’
because policies that incentivize multi-
sectorial collaborations are relatively
new, and they do not yet map to the
current stage for biotechnologies in the
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novel therapies. Evidence of efficacy in
multisectorial research still focuses on
traditional academic outputs, such as
number and quality of scientific publica-
tions. For example, the Innovative Medi-
cines Initiative (IMI) is a public private
partnership designed to accelerate drug
development in Europe. As a funder of
precompetitive consortia, IMI policies on
IPRs facilitate the sharing of data and
materials, at a minimum among members
of each funded consortium. The most
recent report on effectiveness indicates
a higher level of cross-sector publications
and citations to IMI publications than
average. Whether citation counts trans-
late to practical applications or commer-
cial products remains to be seen, but the
indicator is at least pointing in the right
direction.
Collaborative models in genomics de-
pended on shared infrastructure com-
bined with open science policies for data
release and sharing of research tools
(see Caulfield et al., 2012 for a tabling
of key policies in genomics and stem
cell research). Funding agencies adopted
and promoted open science policies and
enforced them in grant applications and
through agreements with leading journals
for data deposition prior to publication.
GenBank, dbGaP, and the UK Biobank
support open science policies in geno-
mics research. Patient groups, frustrated
with the slow pace of therapeutic devel-
opment, are likewise initiating and sup-
porting the creation of data sharing
infrastructure, which links genomics
data with patient records. For example,
Genetic Alliance’s new ‘‘Registries for
All’’ enables individuals to share their
information for use in academia and/or
industry. Reg4ALL aims to accelerate
clinical translation by creating well-char-
acterized cohorts of individuals that can
participate in, and even initiate, clinical
trials. Such movements have flourished
in the open science ecosystem of geno-
mics, but seem less thoroughly explored
in stem cell research and its applications,
likely due to the relative youth of the
field and the greater complexities and
infrastructure requirements of sharing
cell lines versus data, although specific
patient communities in genomics are
providing access to tissue samples. For
example, in 2003, the Alpha-1 Antitrypsin
Deficiency community established theAlpha-1 Foundation DNA and Tissue
Bank, with over 2,300 tissue samples
and related medical information available
to researchers.
For stem cells, sharing norms have
focused on hESC and iPSC lines and the
information associated with them. Levine
(2011) showed that scientists were
experiencing difficulties in accessing
hESC lines from their peers, and that
these limits on sharing drove their choice
and use of lines. WARF’s original restric-
tive policies and high licensing costs
limited the distribution of its hESC lines
through WiCell (McCormick, et al., 2009).
Harvard Stem Cell Institute’s (HSCI) less
restrictive distribution terms and lower
fee structure correlated with broader
distribution (McCormick, et al., 2009).
WiCell later lowered fees and reduced
some reach-through use restrictions.
Transactional friction in stem cell research
prompted the Hinxton Group to recom-
mend hubs for accessing information
about cell lines as well as the develop-
ment and coordination of international
stem cell banks and human tissue and
cell repositories, taking a leaf out of the
genomics book. Recently, CIRM has
developed an hPSC/iPSC repository,
and the UK has launched a national
iPSC bank through the Human Induced
Pluripotent Stem Cell Initiative (HIPSCI)
funded by the Medical Research Council
and Wellcome Trust. In a feat of
academic-commercial collaboration sup-
ported by IMI, StemBANCC will derive,
characterize, and make available 1,500
iPSC lines. While there has been no
mention of collaboration among the three
banks, their development promotes and
facilitates the sharing of common lines.
However, it is important to note that
stem cell banks and registries face com-
plex issues of informed consent and the
identifiability of individual donors—an
ongoing and evolving challenge in both
genomics and stem cell science (Math-
ews et al., 2011) that only serves to bolster
the case for the latter to learn from the
former.
Concluding Thoughts
The road to innovative therapies in the
clinic is lengthy and difficult and requires
highly collaborative research among
academia, industry, and, increasingly,
patient organizations. Funders, journals,
and other policy makers must thereforeCell Stem Ceset policies for the management of IPRs
that create incentives for collaborative,
precompetitive environments that pro-
mote rapid translation of promising thera-
pies to the clinic. Academic institutions,
in particular, must recognize that key
patents over research tools are likely to
expire before clinical application, and
such patents may, in fact, run counter
to their mission of advancing human
knowledge, especially where patent
rights become a lever for enforcing use
restrictions in R&D (both public and
private). A for-profit royalty model for the
distribution of research tools basically
comprises a tax on other publicly funded
research institutions and imposes trans-
actional friction on a process that is
already slow and arduous. Nevertheless,
the establishment of data and materials-
sharing infrastructure and collaborative
policies in stem cell research are steps
in the right direction. Stem cell research
may well benefit from further engagement
with and reference to the more mature
and intimately related field of genomics,
especially with respect to the enforce-
ment of data and materials sharing pol-
icies supported by infrastructure.
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